A girl presenting with intractable seizure and decreased visual acuity

Çelebi Kocaoğlu a, Fatih Akın a, Ahmet Sert a, Hüseyin Çakşen b, Vefa Öner c, Cengizhan Kılıçaslan a, Şükrü Arslan a

aDepartment of Pediatrics, Konya Education and Research Hospital, Konya, Turkey
bDepartment of Pediatrics, Faculty of Medicine, Yüzüncü Yıl University, Van, Turkey
cDepartment of Radiology, Konya Education and Research Hospital, Konya, Turkey

Abstract. Neuronal ceroid lipofuscinoses are the most common neurodegenerative childhood-onset disorders characterized by autosomal recessive inheritance, epileptic seizures, progressive psychomotor deterioration, visual failure, and premature death. At least eleven subtypes of childhood-onset neuronal ceroid lipofuscinoses have been identified. The most common types are the infantile and classic juvenile forms. In this article, we present a 5-year-old girl with late infantile neuronal ceroid lipofuscinosis who presented with seizures and decreased visual acuity. She was healthy and her developmental milestones were normal until 3 years of age. At the age of 3-year-old, her intractable seizures started and decreased visual acuity was recognized. Based on the clinical findings and enzymatic test results, she was diagnosed as late-infantile ceroid lipofuscinosis.

Key words: Neuronal ceroid lipofuscinosis, seizure, visual failure

1. Introduction

Neuronal ceroid lipofuscinoses (NCL) is a group of inherited, progressive, neurodegenerative disorders, which are accepted to be the most common (1 in 12,500 births) neurodegenerative storage disorders of childhood (1-3). According to age of onset, and clinical and pathological findings, the disorders are classified into the infantile, late infantile, juvenile, and adult-onset NCL, as well as a heterogeneous group of atypical subtypes. Late infantile neuronal ceroid lipofuscinosis (LINCL) is considered to be the second common form of NCLs. Classic LINCL presents at the ages of 2 to 4 years. It is characterized by progressive myoclonic epilepsy, ataxia, mental deterioration, and visual failure. The symptomatology usually evolves over a period of months. Parents or healthcare providers notice a previously normal child begin to develop vision problems or seizures. Over time, affected children develop worsening seizures, progressive loss of sight and motor skills, mental impairment, and dementia. The disease is often fatal by the late teens or twenties (2-5).

In this article, we present a 5-year-old girl with LINCL diagnosed at 3 years of age after experiencing seizures and decreased visual acuity.

2. Case report

At 3 years of age, a previously healthy girl was admitted to a local hospital with generalized tonic-clonic seizure and decreased visual acuity. Her birth history was normal and her developmental milestones were normal until 3 years of age. Her uncle had a history of epilepsy and was still on treatment. She had abnormal magnetic resonance imaging and abnormal electroencephalogram (EEG). EEG showed spikes in the temporal lobe. She was started on valproic acid (15 mg/kg/day) and was gradually increased to 30 mg/kg/day. Her parents continued to report breakthrough seizure activity while she was taking valproic acid. At 4 years of age, she was still experiencing breakthrough myoclonic
seizures. Another EEG was abnormal, with the presence of brief runs of 2 to 3 Hz generalized spike and wave activity lasting about 2 to 4 seconds.

In addition, brief runs of 2 to 3 Hz generalized spike and wave activity during photic stimulation were noted. Clonazepam was added to her medication regime after this EEG, which was gradually increased to 0.3 mg/kg/day.

At 5 years of age, her initial neurological examination showed dysarthria and nystagmus. Her Parents reported that the myoclonic seizure activity stopped since adding Clonazepam, additionally her parents reported a slight improvement in the generalized tonic clonic seizure activity since adding valproic acid. On laboratory analysis, a complete blood count, liver and renal function tests, urinary organic acid analysis, and serum aminoacid chromatography were normal. Serum lactate and ammonia levels were also normal. No tripeptidyl-peptidase 1 activity on blood, which indicates late-infantile ceroid lipofuscinosis, was noted. Biopsy and mutation analysis was not performed because of her parents' refusal. Magnetic resonance imaging (MRI) showed diffuse cerebral, cerebellar atrophy and atrophy of corpus collosum (Figures 1, 2 and 3). EEG showed spikes in the temporal lobe. Ophthalmological examination showed bilateral macular degeneration (Figures 4 and 5).
Table 1. Defined neuronal ceroid lipofuscinosis (NCL) types and their mutations in children

<table>
<thead>
<tr>
<th>Disease</th>
<th>Gene involved</th>
<th>Chromosome location</th>
<th>Gene product</th>
</tr>
</thead>
<tbody>
<tr>
<td>Congenital NCL</td>
<td>Not known</td>
<td>Not known</td>
<td>Not known</td>
</tr>
<tr>
<td>Infantile NCL</td>
<td>CLN1</td>
<td>1p32</td>
<td>Lysosomal palmitoyl protein thioesterase</td>
</tr>
<tr>
<td>Classic late-infantile NCL</td>
<td>CLN2</td>
<td>11p15</td>
<td>Lysosomal pepstatin-insensitive peptidase</td>
</tr>
<tr>
<td>Finnish variant late-infantile NCL</td>
<td>CLN5</td>
<td>13q31-32</td>
<td>Lysosomal transmembrane CLN5 protein</td>
</tr>
<tr>
<td>Variant late-infantile/early juvenile NCL</td>
<td>CLN6</td>
<td>15q21-23</td>
<td>Not known</td>
</tr>
<tr>
<td>Variant late-infantile NCL, Turkish</td>
<td>CLN7</td>
<td>Not known</td>
<td>Not known</td>
</tr>
<tr>
<td>Variant late-infantile NCL with GRODs</td>
<td>CLN1</td>
<td>1p32</td>
<td>Lysosomal palmitoyl protein thioesterase</td>
</tr>
<tr>
<td>Classic juvenile NCL</td>
<td>CLN3</td>
<td>16p12</td>
<td>Lysosomal transmembrane CLN3 protein</td>
</tr>
<tr>
<td>Northern epilepsy/EPMR</td>
<td>CLN8</td>
<td>8p23</td>
<td>Membrane protein</td>
</tr>
<tr>
<td>Variant juvenile NCL with GRODs</td>
<td>CLN1</td>
<td>1p32</td>
<td>Lysosomal palmitoyl protein thioesterase</td>
</tr>
<tr>
<td>Variant juvenile NCL</td>
<td>CLN2</td>
<td>11p15</td>
<td>Lysosomal pepstatin-insensitive peptidase</td>
</tr>
</tbody>
</table>

GRODs: Granular osmophilic deposits, EPMR: Progressive epilepsy with mental retardation

Based on the clinical findings and enzymatic test results, she was diagnosed as late-infantile ceroid lipofuscinosis. On the 4th month of follow up, she was still on clonazepam and valproic acid therapy and her myoclonic seizures continued.

4. Discussion

NCLs are a group of autosomal recessive inherited disorders of childhood that share a number of features (5). They are characterized by progressive blindness, neurodegeneration, and the accumulation of auto fluorescent lipopigment material in neurons and other cell types. NCLs were firstly reported at the end of 19th century. LINCL was first described by Jansky in 1908 and was differentiated as a second form of NCL by Bielschowsky in 1913 (3). The disease is caused by mutations in the gene encoding tripeptidyl-peptidase 1. The age of onset ranges from 2 to 11 years. Deterioration in mental capacity is the leading presenting symptom. The seizures are myoclonic, akinetic or tonic clonic and usually refractory to anticonvulsant therapy as in our patient. The loss of motor, mental and visual function is progressive and within a few months, the child progresses a chronic vegetative state. Death usually occurs nearly 10 years after diagnosis (27). Neuroimaging studies are characterized by progressive cerebral atrophy in all types of NCL (3, 4). Our patient had diffuse cerebral, cerebellar and corpus callosum atrophy on.

NCL is associated with defects in eight different genes (CLN1-CLN8) (8). Several recurrent mutations account for 80% of all cases of the disease (Table 1). In addition, more than 100 rare CLN gene mutations causing NCL were reported. A mutation in CLN7, which has not yet been identified, causes a Turkish variant of late infantile NCL, with onset at ages 1-6 years (9).

There is no specific treatment known that can cure or reverse the symptoms of NCLs. Seizures can be managed with anticonvulsant therapy (3-9).

Symptoms of NCLs are linked to the buildup of substances called lipofuscins in the body’s tissues. The lipofuscins are made up of fats and proteins. The lipopigments (lipofuscins) build up in cells of the brain, eye, skin, muscle, and other tissues. Inside the cells, the pigments form deposits with distinctive shapes. These deposits can be seen under an electron microscope. The presence of these on a sample of skin or blood is used to diagnose Batten’s disease (10).

In conclusion, we suggest that NCL should be suspected in previously normal child who develops intractable myoclonic epilepsy and
visual failure. Increased suspicion of this rare disorder would prevent diagnostic delay as well as a misdiagnosis.

References